Corvus Pharmaceuticals (CRVS) Receivables - Net (2022 - 2026)

Corvus Pharmaceuticals' Receivables - Net history runs 5 years deep, the most recent figure standing at $43000.0 for Q1 2026.

• On a quarterly basis, Receivables - Net fell 45.57% year-over-year to $43000.0 in Q1 2026; TTM through Mar 2026 was $43000.0, a 45.57% decrease from a year earlier, with the FY2025 full-year figure at $37000.0, down 50.67% from the prior year.
• Receivables - Net grew to $43000.0 in Q1 2026 per CRVS's latest filing, from $37000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $588000.0 in Q4 2022 and bottomed at $11000.0 in Q3 2023.
• The 5-year median for Receivables - Net is $40000.0 (2025), against an average of $92333.3.
• Across the five-year window, Receivables - Net slumped 95.58% in 2023 and surged 536.36% in 2024, its largest moves.
• Year by year, Receivables - Net stood at $588000.0 in 2022, then slumped by 95.58% to $26000.0 in 2023, then soared by 188.46% to $75000.0 in 2024, then plunged by 50.67% to $37000.0 in 2025, then rose by 16.22% to $43000.0 in 2026.
• Per Business Quant, the three latest CRVS Receivables - Net figures stand at $43000.0 (Q1 2026), $37000.0 (Q4 2025), and $32000.0 (Q3 2025).